Stay updated with breaking news from Capital Commitment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leuven, BELGIUM, Boston, MA, US - November 4, 2022 - 7 PM CET Oxurion NV(Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies
Negma Group has converted 120 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Negma Group's EUR 30 million Capital Commitment1 that will allow Oxurion
Investegate announcements from Oxurion NV, Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Investegate announcements from Oxurion NV, Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group hasconverted580convertible bonds in Oxurion resulting in a EUR1,450,000capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment 1 that will allow Oxurion to focus on